Logo image of SLXN

SILEXION THERAPEUTICS CORP (SLXN) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:SLXN - KYG1281K1307 - Common Stock

2.76 USD
-0.07 (-2.47%)
Last: 12/1/2025, 8:00:03 PM
2.73 USD
-0.03 (-1.09%)
After Hours: 12/1/2025, 8:00:03 PM
Fundamental Rating

1

Overall SLXN gets a fundamental rating of 1 out of 10. We evaluated SLXN against 534 industry peers in the Biotechnology industry. SLXN has a bad profitability rating. Also its financial health evaluation is rather negative. SLXN has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year SLXN has reported negative net income.
In the past year SLXN has reported a negative cash flow from operations.
SLXN had negative earnings in 4 of the past 5 years.
SLXN had negative operating cash flow in 4 of the past 5 years.
SLXN Yearly Net Income VS EBIT VS OCF VS FCFSLXN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 -5M -10M -15M

1.2 Ratios

With a Return On Assets value of -307.83%, SLXN is not doing good in the industry: 93.82% of the companies in the same industry are doing better.
SLXN has a worse Return On Equity (-14870.83%) than 83.52% of its industry peers.
Industry RankSector Rank
ROA -307.83%
ROE -14870.83%
ROIC N/A
ROA(3y)-224.56%
ROA(5y)-174.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SLXN Yearly ROA, ROE, ROICSLXN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 1K -1K -2K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for SLXN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SLXN Yearly Profit, Operating, Gross MarginsSLXN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

2

2. Health

2.1 Basic Checks

The number of shares outstanding for SLXN has been increased compared to 1 year ago.
SLXN has a worse debt/assets ratio than last year.
SLXN Yearly Shares OutstandingSLXN Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 5M 10M
SLXN Yearly Total Debt VS Total AssetsSLXN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

SLXN has an Altman-Z score of -17.79. This is a bad value and indicates that SLXN is not financially healthy and even has some risk of bankruptcy.
SLXN has a Altman-Z score of -17.79. This is amonst the worse of the industry: SLXN underperforms 83.15% of its industry peers.
A Debt/Equity ratio of 26.58 is on the high side and indicates that SLXN has dependencies on debt financing.
SLXN's Debt to Equity ratio of 26.58 is on the low side compared to the rest of the industry. SLXN is outperformed by 83.15% of its industry peers.
Industry RankSector Rank
Debt/Equity 26.58
Debt/FCF N/A
Altman-Z -17.79
ROIC/WACCN/A
WACCN/A
SLXN Yearly LT Debt VS Equity VS FCFSLXN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

SLXN has a Current Ratio of 2.44. This indicates that SLXN is financially healthy and has no problem in meeting its short term obligations.
SLXN has a Current ratio of 2.44. This is in the lower half of the industry: SLXN underperforms 69.66% of its industry peers.
SLXN has a Quick Ratio of 2.44. This indicates that SLXN is financially healthy and has no problem in meeting its short term obligations.
The Quick ratio of SLXN (2.44) is worse than 67.60% of its industry peers.
Industry RankSector Rank
Current Ratio 2.44
Quick Ratio 2.44
SLXN Yearly Current Assets VS Current LiabilitesSLXN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

SLXN shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -2173.84%.
EPS 1Y (TTM)-2173.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-184.15%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 14.49% on average over the next years. This is quite good.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y92.88%
EPS Next 2Y39.87%
EPS Next 3Y25.08%
EPS Next 5Y14.49%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
SLXN Yearly EPS VS EstimatesSLXN Yearly EPS VS EstimatesYearly EPS VS Estimates 2024 2025 2026 2027 2028 2029 -50 -100 -150

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

SLXN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SLXN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SLXN Price Earnings VS Forward Price EarningsSLXN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SLXN Per share dataSLXN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -100 -200 -300

4.3 Compensation for Growth

SLXN's earnings are expected to grow with 25.08% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y39.87%
EPS Next 3Y25.08%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for SLXN!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SILEXION THERAPEUTICS CORP

NASDAQ:SLXN (12/1/2025, 8:00:03 PM)

After market: 2.73 -0.03 (-1.09%)

2.76

-0.07 (-2.47%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2025-11-12/bmo
Earnings (Next)N/A N/A
Inst Owners9.07%
Inst Owner ChangeN/A
Ins Owners0.11%
Ins Owner Change0%
Market Cap8.64M
Revenue(TTM)N/A
Net Income(TTM)-17.84M
Analysts82.86
Price Target12.24 (343.48%)
Short Float %5.08%
Short Ratio0.24
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-16.76%
Min EPS beat(2)-17.65%
Max EPS beat(2)-15.86%
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-50%
PT rev (3m)-50%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 71.99
P/tB 71.99
EV/EBITDA N/A
EPS(TTM)-350.07
EYN/A
EPS(NY)-7.56
Fwd EYN/A
FCF(TTM)-4.16
FCFYN/A
OCF(TTM)-4.15
OCFYN/A
SpS0
BVpS0.04
TBVpS0.04
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -307.83%
ROE -14870.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-224.56%
ROA(5y)-174.87%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 26.58
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.44
Quick Ratio 2.44
Altman-Z -17.79
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-2173.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-184.15%
EPS Next Y92.88%
EPS Next 2Y39.87%
EPS Next 3Y25.08%
EPS Next 5Y14.49%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-1312.86%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-945.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-943.32%
OCF growth 3YN/A
OCF growth 5YN/A

SILEXION THERAPEUTICS CORP / SLXN FAQ

What is the ChartMill fundamental rating of SILEXION THERAPEUTICS CORP (SLXN) stock?

ChartMill assigns a fundamental rating of 1 / 10 to SLXN.


What is the valuation status of SILEXION THERAPEUTICS CORP (SLXN) stock?

ChartMill assigns a valuation rating of 1 / 10 to SILEXION THERAPEUTICS CORP (SLXN). This can be considered as Overvalued.


What is the profitability of SLXN stock?

SILEXION THERAPEUTICS CORP (SLXN) has a profitability rating of 0 / 10.


What is the earnings growth outlook for SILEXION THERAPEUTICS CORP?

The Earnings per Share (EPS) of SILEXION THERAPEUTICS CORP (SLXN) is expected to grow by 92.88% in the next year.